NO20001515L - Vitronektin reseptor-antagonist - Google Patents

Vitronektin reseptor-antagonist

Info

Publication number
NO20001515L
NO20001515L NO20001515A NO20001515A NO20001515L NO 20001515 L NO20001515 L NO 20001515L NO 20001515 A NO20001515 A NO 20001515A NO 20001515 A NO20001515 A NO 20001515A NO 20001515 L NO20001515 L NO 20001515L
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
NO20001515A
Other languages
English (en)
Other versions
NO20001515D0 (no
Inventor
William E Bondinelli
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001515D0 publication Critical patent/NO20001515D0/no
Publication of NO20001515L publication Critical patent/NO20001515L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En forbindelse med formel (I) er beskrevet som er en vitronektin-reseptorantagonist og er nyttige ved behandling av osteoporose: eller et farmasøytisk godtagbart salt derav.
NO20001515A 1997-09-24 2000-03-23 Vitronektin reseptor-antagonist NO20001515L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5986797P 1997-09-24 1997-09-24
PCT/US1998/019987 WO1999015178A1 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Publications (2)

Publication Number Publication Date
NO20001515D0 NO20001515D0 (no) 2000-03-23
NO20001515L true NO20001515L (no) 2000-03-23

Family

ID=22025805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001515A NO20001515L (no) 1997-09-24 2000-03-23 Vitronektin reseptor-antagonist

Country Status (13)

Country Link
EP (1) EP1023073A1 (no)
JP (1) JP2002500162A (no)
KR (1) KR20010024249A (no)
CN (1) CN1271284A (no)
AU (1) AU9578798A (no)
BR (1) BR9813214A (no)
CA (1) CA2304000A1 (no)
HU (1) HUP0003931A2 (no)
IL (1) IL135188A0 (no)
NO (1) NO20001515L (no)
PL (1) PL339414A1 (no)
TR (1) TR200000786T2 (no)
WO (1) WO1999015178A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
EP2428226A1 (en) 2001-10-22 2012-03-14 The Scripps Research Institute Antibody targeting compounds
EP1628949A4 (en) 2003-04-04 2008-07-02 Smithkline Beecham Corp PROCESS AND INTERMEDIATE PRODUCTS FOR PREPARING BENZAZEPINES
CA2554644C (en) 2004-02-02 2015-06-16 Pioneer Hi-Bred International, Inc. Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
MX2009007597A (es) 2007-01-18 2009-07-22 Merck Patent Gmbh Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
JP5359879B2 (ja) 2007-11-16 2013-12-04 宇部興産株式会社 ベンズアゼピノン化合物
WO2009111679A2 (en) * 2008-03-06 2009-09-11 Smithkline Beecham Corporation Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
US20120095215A1 (en) 2009-03-30 2012-04-19 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of eye diseases
BRPI1011206A2 (pt) 2009-05-25 2016-03-15 Merck Patent Gmbh administração contínua de ligantes de integrina para tratar câncer
WO2011082310A2 (en) 2009-12-30 2011-07-07 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
US20110167516A1 (en) 2009-12-30 2011-07-07 Pioneer Hi-Bred International, Inc. Methods and compositions for the introduction and regulated expression of genes in plants
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
CN1271284A (zh) 2000-10-25
WO1999015178A1 (en) 1999-04-01
TR200000786T2 (tr) 2000-08-21
IL135188A0 (en) 2001-05-20
AU9578798A (en) 1999-04-12
NO20001515D0 (no) 2000-03-23
CA2304000A1 (en) 1999-04-01
HUP0003931A2 (hu) 2001-10-28
EP1023073A1 (en) 2000-08-02
PL339414A1 (en) 2000-12-18
KR20010024249A (ko) 2001-03-26
BR9813214A (pt) 2000-08-29
JP2002500162A (ja) 2002-01-08

Similar Documents

Publication Publication Date Title
NO20001515L (no) Vitronektin reseptor-antagonist
NO20001514L (no) Vitronectin-reseptor-antagonist
NO983002L (no) Vitronectin-reseptor-antagonister
NO983003L (no) Vitronectin-reseptor-antagonister
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
EP1019045A4 (en) ANTITHROMBOTIC AGENTS
DK0896533T3 (da) Pentafluorbenzensulfonamider og analoger
ATE306261T1 (de) Antithrombosemittel
GB9514473D0 (en) Chemical compounds
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
FI964815A0 (fi) Piperatsiinijohdoksia 5-HT1A antagonisteina
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
NL300344I1 (nl) Nucleotide-analogen
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
AU2002213421A1 (en) Condensed pyridoindole derivatives
BR9812340A (pt) Antagonistas de receptor de vitronectina
NO975975L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
DK1468689T3 (da) 2-methyl-thieno-benzodiazepine formulation
AP1534A (en) Vitronectin receptor antagonists.
NO974400L (no) Kombinasjonspreparater inneholdende benazepril eller benazeprilat og valsartan
WO1998031704A3 (en) Tachykinin antagonists
WO2001017959A3 (en) Vitronectin receptor antagonists
NO20004545L (no) FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
WO2000007544A3 (en) Vitronectin receptor antagonists
DK0980383T3 (da) Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application